NCT06353646 — Wu Wenming cancer immunotherapy trial
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Registry record
| Registry ID | NCT06353646 ↗ |
|---|---|
| Lead sponsor | Wu Wenming |
| Collaborators | NeoCura |
| Phase | Phase NA |
| Status | Recruiting |
| Indication | Pancreatic Cancer |
| Enrollment | 28 participants (target) |
| Start date | 2024-03-12 |
| Primary completion | 2026-06 (est.) |
| Last registry update | 13 Feb 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06353646), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06353646?
NCT06353646 (XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer) is registered on ClinicalTrials.gov as Phase NA, sponsored by Wu Wenming.
Is NCT06353646 recruiting?
As of the 2026-02-13 registry update, NCT06353646 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06353646?
The lead sponsor is Wu Wenming. Collaborators: NeoCura.
What condition does NCT06353646 study?
The registered condition is Pancreatic Cancer. Primary completion is listed as 2026-06 (estimated).
Are results available for NCT06353646?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06353646.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.